Outfitter Financial LLC Purchases 460 Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Outfitter Financial LLC increased its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 8.3% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 5,970 shares of the medical equipment provider’s stock after purchasing an additional 460 shares during the quarter. Outfitter Financial LLC’s holdings in Zimmer Biomet were worth $631,000 at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of ZBH. Equity Investment Corp bought a new position in shares of Zimmer Biomet during the 3rd quarter worth about $70,104,000. Hotchkis & Wiley Capital Management LLC lifted its stake in Zimmer Biomet by 49.1% during the third quarter. Hotchkis & Wiley Capital Management LLC now owns 1,752,298 shares of the medical equipment provider’s stock worth $189,161,000 after purchasing an additional 577,320 shares during the period. Van ECK Associates Corp lifted its stake in Zimmer Biomet by 12.4% during the third quarter. Van ECK Associates Corp now owns 3,736,761 shares of the medical equipment provider’s stock worth $391,239,000 after purchasing an additional 411,163 shares during the period. Thompson Siegel & Walmsley LLC bought a new stake in shares of Zimmer Biomet in the 3rd quarter valued at approximately $41,588,000. Finally, FMR LLC raised its holdings in shares of Zimmer Biomet by 27.6% in the 3rd quarter. FMR LLC now owns 750,336 shares of the medical equipment provider’s stock worth $80,999,000 after buying an additional 162,384 shares in the last quarter. Institutional investors and hedge funds own 88.89% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have weighed in on ZBH shares. Stifel Nicolaus upped their price target on Zimmer Biomet from $130.00 to $138.00 and gave the company a “buy” rating in a research report on Thursday, January 23rd. Truist Financial restated a “hold” rating and issued a $113.00 target price (down previously from $118.00) on shares of Zimmer Biomet in a research note on Monday, February 10th. JMP Securities reissued a “market outperform” rating and set a $140.00 price target on shares of Zimmer Biomet in a report on Friday, February 7th. Raymond James reduced their price target on shares of Zimmer Biomet from $126.00 to $119.00 and set an “outperform” rating on the stock in a research report on Friday, February 7th. Finally, JPMorgan Chase & Co. raised shares of Zimmer Biomet from a “neutral” rating to an “overweight” rating and raised their price objective for the stock from $125.00 to $128.00 in a report on Tuesday, December 17th. Two investment analysts have rated the stock with a sell rating, eleven have given a hold rating and nine have issued a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $124.15.

Zimmer Biomet Stock Up 0.3 %

Shares of NYSE:ZBH opened at $103.64 on Friday. The company has a 50 day moving average of $105.90 and a 200-day moving average of $107.48. Zimmer Biomet Holdings, Inc. has a one year low of $97.69 and a one year high of $133.90. The stock has a market cap of $20.63 billion, a price-to-earnings ratio of 23.29, a P/E/G ratio of 1.95 and a beta of 1.02. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.91 and a quick ratio of 0.99.

Zimmer Biomet (NYSE:ZBH) last issued its earnings results on Thursday, February 6th. The medical equipment provider reported $2.31 EPS for the quarter, beating the consensus estimate of $2.30 by $0.01. Zimmer Biomet had a net margin of 11.77% and a return on equity of 12.99%. During the same quarter in the previous year, the business posted $2.20 earnings per share. On average, sell-side analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current year.

Zimmer Biomet Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, January 31st. Stockholders of record on Monday, December 30th were paid a $0.24 dividend. The ex-dividend date of this dividend was Monday, December 30th. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.93%. Zimmer Biomet’s dividend payout ratio (DPR) is presently 21.57%.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.